Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs AMOXICILLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis),Lower respiratory tract infections (e.g., community-acquired pneumonia, acute exacerbation of chronic bronchitis),Genitourinary tract infections (e.g., cystitis, urethritis),Skin and skin structure infections,Helicobacter pylori eradication (in combination with clarithromycin and a proton pump inhibitor),Lyme disease (early localized),Prophylaxis of infective endocarditis (for dental procedures in high-risk patients),Off-label: Anthrax (post-exposure prophylaxis), uncomplicated gonorrhea
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
Terminal elimination half-life: 1-1.5 hours in normal renal function. Prolonged to 7-20 hours in end-stage renal disease.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid (inactive). It is not extensively metabolized by the liver; about 60% of an oral dose is excreted unchanged in urine.
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: up to 20% excreted in bile. Fecal: minimal.
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
17-20% bound to serum albumin.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
0.3-0.4 L/kg. Distributes well into most body fluids and tissues, including pleural, peritoneal, and synovial fluids; limited CNS penetration unless meninges inflamed.
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
Oral: 74-92% (absorption is not food-dependent). IM: approximately 100%.
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
Cr Cl 30-50 m L/min: 250-500 mg every 8-12 hours. Cr Cl 10-29 m L/min: 250-500 mg every 12 hours. Cr Cl <10 m L/min: 250-500 mg every 24 hours. Hemodialysis: 250-500 mg every 24 hours, supplemented during and after dialysis.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
No dose adjustment required for mild to moderate hepatic impairment. Severe hepatic impairment (Child-Pugh class C): use with caution; specific dosing guidelines not established.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
Children >3 months: 20-40 mg/kg/day divided every 8 hours for mild to moderate infections; 40-90 mg/kg/day divided every 8-12 hours for severe infections. Maximum 3 g/day.
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
No specific dose adjustment; monitor renal function and adjust based on Cr Cl. Caution with concurrent nephrotoxic agents.
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
No FDA black box warning.
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Hypersensitivity reactions including anaphylaxis have been reported; contraindicated in patients with known penicillin allergy.,Clostridium difficile-associated diarrhea (CDAD) may occur and must be considered in patients presenting with diarrhea after antibiotic use.,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur; discontinue if rash or other allergic signs appear.,Use caution in patients with renal impairment; dosage adjustment may be necessary.,Prolonged use may result in superinfection with non-susceptible organisms.
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
History of hypersensitivity reaction to any penicillin or beta-lactam antibiotic.,Infectious mononucleosis (increases risk of maculopapular rash).,Phenylketonuria (some formulations contain aspartame).
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
No significant food interactions. Absorption is not affected by food; may be taken with meals to reduce gastrointestinal upset. Avoid concurrent alcohol consumption as it may increase risk of side effects like nausea and vomiting.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and third trimesters: use only if clearly needed; no known fetal harm, but caution due to maternal physiological changes.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Amoxicillin is excreted into breast milk in small amounts (M/P ratio approximately 0.014-0.015). Considered compatible with breastfeeding; potential for diarrhea or allergic sensitization in infant, but generally safe.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
No dose adjustment required for amoxicillin in pregnancy; however, increased renal clearance and expanded plasma volume may lower serum concentrations. For severe infections, consider standard dosing with monitoring of clinical response.
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
For streptococcal pharyngitis, amoxicillin 50 mg/kg once daily (max 1 g) is as effective as multiple daily doses and improves adherence. In penicillin-allergic patients, the cross-reactivity risk with cephalosporins is low; a cephalosporin can be used if no history of immediate-type hypersensitivity. Amoxicillin is not effective against penicillinase-producing staphylococci or most Gram-negative organisms due to beta-lactamase production. Monitor for rash in patients with infectious mononucleosis (ampicillin rash occurs more frequently, but amoxicillin also has increased risk). Dose adjustment needed for creatinine clearance <30 m L/min.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).
Take exactly as prescribed; complete the full course even if you feel better.,Can be taken with or without food; if stomach upset occurs, take with a meal.,Swallow capsules whole; do not crush or chew; oral suspension shake well before each dose.,Skip missed dose if almost time for next; do not double dose.,Seek immediate medical help for signs of allergic reaction: hives, difficulty breathing, swelling of face/lips/tongue.,May cause diarrhea; contact doctor if watery or bloody stools.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Avoid large amounts of grapefruit juice as it may affect absorption (limited clinical significance).
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs AMOXICILLIN, answered by our medical review team.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) is a Opioid Agonist that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.. AMOXICILLIN is a Penicillin Antibiotic that works by Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and AMOXICILLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ASPIRIN (HALF-STRENGTH) is: Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.. The standard adult dose of AMOXICILLIN is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and AMOXICILLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ASPIRIN (HALF-STRENGTH) is classified as Category D/X. Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated w. AMOXICILLIN is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.